There are 2789 resources available
Discussion LBA50, LBA51 & 1194MO
Presenter: David Gandara
Session: Mini oral session - NSCLC, metastatic
Resources:
Slides
Webcast
Discussion 828MO, 829MO and 830MO
Presenter: Andrew Davies
Session: Mini oral session - Haematological malignancies
Resources:
Slides
Webcast
Discussion 831MO and 832MO
Presenter: Ingrid Glimelius
Session: Mini oral session - Haematological malignancies
Resources:
Slides
Webcast
Discussion 4MO, 5MO and 6MO
Presenter: Ruth Plummer
Session: Mini oral session - Basic science
Resources:
Slides
Webcast
Discussion 578MO and 579MO
Presenter: Giulia Baciarello
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
Discussion 7MO, 1801MO and 1802MO
Presenter: Christian Ottensmeier
Session: Mini oral session - Basic science
Resources:
Slides
Webcast
Discussion 723MO and 724MO
Presenter: Ana Oaknin
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
Discussion LBA49, 1192MO and 1193MO
Presenter: Sai-Hong Ou
Session: Mini oral session - NSCLC, metastatic
Resources:
Slides
Webcast
1192MO - Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
Presenter: Natasha B. Leighl
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1193MO - Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
Presenter: Catherine A. Shu
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast